CSF3 and Decreased total neutrophil count: This stage of study, in sum, recommended that the double dosage regimens of rHSA/G-CSF 2400 μg had tolerable safety profiles on the basis of dose-independent toxicities, and promising efficacy in favor of the management for neutropenia induced by chemotherapy in clinical practice.